查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1698589

抗憂鬱藥物市場機會、成長動力、產業趨勢分析及 2025-2034 年預測

Antidepressant Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球抗憂鬱藥物市場規模達到 187 億美元，預計 2025 年至 2034 年期間的複合年成長率將達到 7.5%。這一成長主要得益於人們對心理健康的日益關注以及對抑鬱症及相關疾病有效治療的需求日益成長。藥物研究的不斷進步推出了針對難治性憂鬱症的創新藥物，可以更快地緩解病情並提高耐受性。仿製抗憂鬱藥物的普及提高了人們的負擔能力，特別是在中低收入地區，而遠距醫療和網路藥局使服務不足地區的個人更容易獲得心理健康治療。

抗憂鬱藥物市場 - IMG1

抗憂鬱藥物調節影響情緒、情緒和行為的神經傳導物質。全球市場根據藥物類別進行細分，選擇性血清素再攝取抑制劑 (SSRI) 在 2024 年佔據 55.8% 的主導市場。其廣泛使用歸因於高效能、副作用少以及在治療憂鬱症、焦慮症、強迫症、恐慌症和創傷後壓力症候群方面的廣泛適用性。通用版本的推出提高了藥物的可及性和可負擔性，進一步鞏固了其市場地位。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 187億美元
預測值 379億美元
複合年成長率 7.5％

根據應用，市場分為廣泛性焦慮症、重度憂鬱症、強迫症、恐慌症和其他病症。重度憂鬱症領域引領市場，到 2024 年將達到 95 億美元。隨著人們認知的提高和對憂鬱症的恥辱感的減少，越來越多的人尋求醫療幫助，從而導致診斷率更高，對抗憂鬱藥物的需求持續增加。長期治療的必要性進一步推動了該領域的成長。

根據給藥途徑，市場分為口服、注射、鼻腔和經皮製劑。口服藥物在 2024 年佔據了相當大的市場佔有率，預計到 2034 年將達到 302 億美元。由於服用方便、價格實惠且安全性得到確認，藥片和膠囊仍然是首選。品牌和仿製口服抗憂鬱藥物均能確保患者廣泛獲得藥物，從而促進該領域繼續佔據主導地位。

就藥物類型而言，市場分為品牌藥和學名藥。受益於強大的行銷策略、品牌忠誠度以及針對難治性憂鬱症的創新，預測期內品牌細分市場預計將以 7.2% 的複合年成長率成長。品牌藥物通常被認為具有卓越的療效和安全性，因此其採用率不斷提高。

分銷管道包括醫院藥房、零售藥房和網路藥房。由於嚴重精神疾病的處方量很大，醫院藥局在 2024 年佔了 57.9% 的市場。這些藥房提供專門的藥物，透過仔細的監測和治療調整確保更好地管理患者。對專業心理健康服務的日益關注繼續支持市場擴張。

2024 年，美國抗憂鬱藥物市值為 68 億美元。精神健康障礙的高盛行率，加上人們意識的提高和醫療保健體系的發達，推動了市場的成長。透過基層醫療醫師和心理健康專家可以獲得抗憂鬱藥物，確保了需求的穩定成長。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 憂鬱症和焦慮症盛行率上升
      • 增加研發投入
      • 對治療療法和心理健康的認知不斷提高
    • 產業陷阱與挑戰
      • 一些抗憂鬱藥物的副作用
      • 顧客對非藥物療法的偏好高於藥物療法
  • 成長潛力分析
  • 監管格局
  • 管道分析
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 策略儀表板

第5章：市場估計與預測：按藥物類別，2021 年至 2034 年

  • 主要趨勢
  • 選擇性血清素再攝取抑制劑（SSRI）
  • 血清素和正腎上腺素再攝取抑制劑（SNRI）
  • 三環抗憂鬱劑 (TCA)
  • 非典型抗憂鬱藥
  • 去甲腎上腺素多巴胺再攝取抑制劑 (NDRI)
  • 單胺氧化酶抑制劑（MAOI）
  • 其他藥物類別

第6章：市場估計與預測：按應用，2021 年至 2034 年

  • 主要趨勢
  • 重度憂鬱症
  • 廣泛性焦慮症
  • 強迫症
  • 恐慌症
  • 其他應用

第7章：市場估計與預測：依管理路線，2021 年至 2034 年

  • 主要趨勢
  • 口服
  • 注射劑
  • 鼻腔
  • 經皮

第8章：市場估計與預測：按藥物類型，2021 年至 2034 年

  • 主要趨勢
  • 品牌
  • 通用的

第9章：市場估計與預測：按配銷通路，2021 年至 2034 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第10章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：公司簡介

  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Intra-Cellular Therapies
  • Janssen Pharmaceuticals
  • NV Organon
  • Novartis
  • Opko Health
  • Otsuka Pharmaceutical
  • Patheon
  • Pfizer
  • Sandoz
  • Sun Pharmaceuticals
  • Takeda Pharmaceuticals
  • Zhejiang NHU Company
簡介目錄
Product Code: 2505

The Global Antidepressant Drugs Market reached USD 18.7 billion in 2024 and is projected to expand at a CAGR of 7.5% between 2025 and 2034. This growth is largely driven by the rising focus on mental health and the increasing need for effective treatments for depression and related disorders. Continuous advancements in pharmaceutical research have introduced innovative drugs targeting treatment-resistant depression, providing faster relief with improved tolerability. The availability of generic antidepressants has enhanced affordability, particularly in low- and middle-income regions, while telemedicine and online pharmacies have made mental health treatments more accessible to individuals in underserved areas.

Antidepressant Drugs Market - IMG1

Antidepressant drugs regulate neurotransmitters that influence mood, emotions, and behavior. The global market is segmented based on drug class, with selective serotonin reuptake inhibitors (SSRIs) holding a dominant 55.8% market share in 2024. Their widespread use is attributed to high efficacy, fewer side effects, and broad applicability in treating depression, anxiety, obsessive-compulsive disorder, panic disorder, and post-traumatic stress disorder. The availability of generic versions has further strengthened their market position by improving accessibility and affordability.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$18.7 Billion
Forecast Value$37.9 Billion
CAGR7.5%

Based on application, the market is categorized into generalized anxiety disorder, major depressive disorder, obsessive-compulsive disorder, panic disorder, and other conditions. The major depressive disorder segment led the market, reaching USD 9.5 billion in 2024. As awareness grows and the stigma around depression declines, more people seek medical assistance, leading to higher diagnosis rates and sustained demand for antidepressant medications. The necessity for long-term treatment further drives growth in this segment.

The market is divided by route of administration into oral, injectable, nasal, and transdermal formulations. The oral segment accounted for a significant portion of the market in 2024 and is projected to reach USD 30.2 billion by 2034. Tablets and capsules remain the preferred choice due to ease of administration, affordability, and established safety profiles. Both branded and generic oral antidepressants contribute to the segment's continued dominance by ensuring broad accessibility for patients.

Regarding medication type, the market is split into branded and generic drugs. The branded segment is expected to grow at a 7.2% CAGR during the forecast period, benefiting from strong marketing strategies, brand loyalty, and innovations aimed at treatment-resistant depression. Branded medications are often perceived as offering superior efficacy and safety, contributing to their increasing adoption.

Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies held a 57.9% market share in 2024 due to the high volume of prescriptions for severe mental health conditions. These pharmacies offer specialized medications, ensuring better patient management through careful monitoring and treatment adjustments. A growing focus on specialized mental health services continues to support market expansion.

The U.S. antidepressant drugs market was valued at USD 6.8 billion in 2024. The high prevalence of mental health disorders, coupled with increasing awareness and a well-developed healthcare system, drives market growth. The accessibility of antidepressants through primary care physicians and mental health specialists ensures a steady rise in demand.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of depression and anxiety disorders
      • 3.2.1.2 Increasing investment in research and development
      • 3.2.1.3 Growing awareness regarding treatment therapies and mental health
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Side effects associated with some antidepressant drugs
      • 3.2.2.2 Customer preference for non-pharmacological therapeutics over pharmacological therapeutics
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Selective serotonin reuptake inhibitors (SSRIs)
  • 5.3 Serotonin and noradrenaline reuptake inhibitors (SNRIs)
  • 5.4 Tricyclic antidepressants (TCAs)
  • 5.5 Atypical antidepressants
  • 5.6 Norepinephrine-dopamine reuptake inhibitor (NDRI)
  • 5.7 Monoamine oxidase inhibitors (MAOIs)
  • 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Major depressive disorder
  • 6.3 Generalized anxiety disorder
  • 6.4 Obsessive-compulsive disorder
  • 6.5 Panic disorder
  • 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Nasal
  • 7.5 Transdermal

Chapter 8 Market Estimates and Forecast, By Medication Type, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Branded
  • 8.3 Generic

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospital pharmacies
  • 9.3 Retail pharmacies
  • 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 Bristol-Myers Squibb
  • 11.2 Eli Lilly and Company
  • 11.3 GlaxoSmithKline
  • 11.4 Intra-Cellular Therapies
  • 11.5 Janssen Pharmaceuticals
  • 11.6 N.V. Organon
  • 11.7 Novartis
  • 11.8 Opko Health
  • 11.9 Otsuka Pharmaceutical
  • 11.10 Patheon
  • 11.11 Pfizer
  • 11.12 Sandoz
  • 11.13 Sun Pharmaceuticals
  • 11.14 Takeda Pharmaceuticals
  • 11.15 Zhejiang NHU Company